Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

DAIICHI SANKYO, INC.

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Subsidiary

Established: 2010-01-01

Employees: 10K

Market Cap: $79B

Website: http://daiichisankyo.us

Clinical Trials

Chemotherapy in Treating Patients Who Have Hematologic Cancer

Phase 1

Completed

Conditions: Myelodysplastic Syndromes
Leukemia

First Posted Date: 2004-07-19

Last Posted Date: 2012-05-16

Lead Sponsor: Daiichi Sankyo

Registration Number: NCT00004047

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

DX-8951f in Treating Patients With Biliary Cancer

Phase 2

Completed

Conditions: Extrahepatic Bile Duct Cancer
Gallbladder Cancer
Liver Cancer

First Posted Date: 2004-04-20

Last Posted Date: 2012-05-16

Lead Sponsor: Daiichi Sankyo

Registration Number: NCT00005938

Locations: 🇺🇸
University of Colorado Cancer Center, Denver, Colorado, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Simmons Cancer Center - Dallas, Dallas, Texas, United States

and more 2 locations

DX-8951f in Treating Patients With Liver Cancer

Phase 2

Completed

Conditions: Liver Cancer

First Posted Date: 2004-04-16

Last Posted Date: 2012-05-16

Lead Sponsor: Daiichi Sankyo

Registration Number: NCT00004108

Locations: 🇺🇸
University of Colorado Cancer Center, Denver, Colorado, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

and more 1 locations

Chemotherapy in Treating Women With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-04-15

Last Posted Date: 2012-05-16

Lead Sponsor: Daiichi Sankyo

Registration Number: NCT00004046

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Chemotherapy in Treating Patients With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2004-04-15

Last Posted Date: 2012-05-16

Lead Sponsor: Daiichi Sankyo

Registration Number: NCT00004045

Locations: 🇺🇸
U.S. Oncology Research Inc., Houston, Texas, United States
🇺🇸
Institute for Drug Development, San Antonio, Texas, United States

DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma

Phase 2

Completed

Conditions: Colorectal Cancer

First Posted Date: 2004-04-08

Last Posted Date: 2012-05-16

Lead Sponsor: Daiichi Sankyo

Registration Number: NCT00080834

Locations: 🇺🇸
University of New Mexico Cancer Research and Treatment Center, Albuquerque, New Mexico, United States
🇺🇸
MD Anderson Cancer Center at University of Texas, Houston, Texas, United States

DJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-02-11

Last Posted Date: 2012-05-16

Lead Sponsor: Daiichi Sankyo

Registration Number: NCT00077077

Locations: 🇺🇸
Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Cancer Therapy and Research Center, San Antonio, Texas, United States

Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma

Phase 2

Completed

Conditions: Sarcoma

First Posted Date: 2003-07-09

Last Posted Date: 2012-05-16

Lead Sponsor: Daiichi Sankyo

Registration Number: NCT00064220

Locations: 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 3 locations

Soblidotin in Treating Patients With Progressive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2003-06-06

Last Posted Date: 2012-05-16

Lead Sponsor: Daiichi Sankyo

Registration Number: NCT00061854

Locations: 🇺🇸
Medical Oncology and Hematology, P.C., Waterbury, Connecticut, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma

Phase 2

Completed

Conditions: Sarcoma

First Posted Date: 2003-03-07

Last Posted Date: 2012-05-16

Lead Sponsor: Daiichi Sankyo

Registration Number: NCT00055939

Locations: 🇺🇸
University of Colorado Cancer Center at University of Colorado Health Sciences Center, Denver, Colorado, United States
🇺🇸
Nemours Children's Clinic, Jacksonville, Florida, United States
🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy